Cover Image

Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy

Glioblastoma multiforme is the most frequent and most malignant primary brain tumor with poor prognosis despite surgical removal and radio-chemotherapy. In this setting, immunotherapeutical strategies have great potential, but the reported repertoire of tumor associated antigens is only for HLA-A*02...

Full description

Saved in:
Bibliographic Details
Main Authors: Neidert, Marian Christoph (Author) , Schoor, Oliver (Author) , Trautwein, Claudia (Author) , Trautwein, Nico (Author) , Christ, Lisa (Author) , Melms, Arthur (Author) , Honegger, Jürgen (Author) , Rammensee, Hans-Georg (Author) , Herold-Mende, Christel (Author) , Dietrich, Pierre-Yves (Author) , Stevanović, Stefan (Author)
Format: Article (Journal)
Language:English
Published: 2013
In: Journal of neuro-oncology
Year: 2013, Volume: 111, Issue: 3, Pages: 285-294
ISSN:1573-7373
DOI:10.1007/s11060-012-1028-8
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s11060-012-1028-8
Get full text
Author Notes:Marian Christoph Neidert, Oliver Schoor, Claudia Trautwein, Nico Trautwein, Lisa Christ, Arthur Melms, Jürgen Honegger, Hans-Georg Rammensee, Christel Herold-Mende, Pierre-Yves Dietrich, Stefan Stevanović
Description
Summary:Glioblastoma multiforme is the most frequent and most malignant primary brain tumor with poor prognosis despite surgical removal and radio-chemotherapy. In this setting, immunotherapeutical strategies have great potential, but the reported repertoire of tumor associated antigens is only for HLA-A*02 positive tumors. We describe the first analysis of HLA-peptide presentation patterns in HLA-A*02 negative glioma tissue combined with gene expression profiling of the tumor samples by oligonucleotide microarrays. We identified numerous candidate peptides for immunotherapy. These are peptides derived from proteins with a well-described role in glioma tumor biology and suitable gene expression profiles such as PTPRZ1, EGFR, SEC61G and TNC. Information obtained from complementary analyses of HLA-A*02 negative tumors not only contributes to the discovery of novel shared glioma antigens, but most importantly provides the opportunity to tailor a patient-individual cocktail of tumor-associated peptides for a personalized, targeted immunotherapeutic approach in HLA-A*02 negative patients.
Item Description:Published online: 23 December 2012
Gesehen am 08.12.2021
Physical Description:Online Resource
ISSN:1573-7373
DOI:10.1007/s11060-012-1028-8

Similar Items